Cocrystal Pharma (COCP) Convertible Debt (2017 - 2018)
Cocrystal Pharma (COCP) posted Convertible Debt of $2.0 million for Q1 2018, up 102.48% sequentially from $1.0 million in Q4 2017.
Cocrystal Pharma (COCP) Convertible Debt (2017 - 2018) Analysis & Trends
Cocrystal Pharma has reported Convertible Debt for 2 years, with the latest figure at $2.0 million in Q1 2018.
- Quarterly Convertible Debt changed N/A year-over-year to $2.0 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $2.0 million (changed N/A YoY) and the FY2017 annual result came in at $1.0 million, changed N/A from the prior year.
- Convertible Debt improved to $2.0 million in Q1 2018 per COCP's latest filing, from $1.0 million in the prior quarter.
- Over five years, Convertible Debt peaked at $2.0 million in Q1 2018 and troughed at $1.0 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - |
| 10 | Cocrystal Pharma | 16.27 Mn | 13.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 2.04 Mn |
| Dec 31, 2017 | 1.01 Mn |